Devyser receives Eurostars grant to develop novel DNA test

News

News | February 2, 2021

Devyser has been awarded a funding of EUR 750,000 through the Eurostars-2 program and will join its efforts with the University Hospital of Zurich to further develop its unique NGS based test for early detection of kidney transplant recipients.

Through this project, Devyser aims to provide a certified CE-IVD kit, including reagents, protocols and software for data analysis ready to implement for routine use.

Link to the full press release:
Devyser receives EUR 750,000 Eurostars grant to develop novel DNA test for early detection of transplant rejection

Contact an expert at Devyser

If you have a question, feel free to send us a message. One of our team members will get in touch with you as soon as possible.

Devyser receives Eurostars grant to develop novel DNA test

Contact an expert at Devyser

Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring

Devyser secures SEK 8.9M five-year tender and strengthens Italian position

Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing

Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market

Devyser receives Eurostars grant to develop novel DNA test

Contact an expert at Devyser

Related Articles

Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring

Devyser secures SEK 8.9M five-year tender and strengthens Italian position

Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing

Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market